Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.532, 2007-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
First-line sunitinib cost-effective alternative to interferon-α in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. :
Access to resources
Recommend
Sunitinib cost-effective alternative to interferon-α in renal cancer
Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. :
Sorafenib a cost-effective option in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 516, 2006-01 ,pp. :
Sunitinib soars ahead in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. :
Superior QOL with sunitinib in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 560, 2008-01 ,pp. :